Please wait while the formulary information is being retrieved.
HYCAMTIN (TOPOTECAN HCL)
- Carcinoma of cervix
- Malignant neoplasm of the ovary
- Small cell lung carcinoma
- Topotecan Iv Solution
- Topotecan Intravenous Powder For Solution
- Hycamtin Intravenous Solution
- Hycamtin Capsule
- By Indication
4 mg intravenous solution
- Infuse 1.5 mg/m2 over 30 minute(s) by intravenous route once daily for 5 consecutive days starting on day 1 of a 21 day course
4 mg intravenous solution
- Infuse 1.5 mg/m2 over 30 minute(s) by intravenous route once daily for 5 consecutive days starting on day 1 of a 21 day course
topotecan 4 mg intravenous solution
- Infuse 1.5 mg/m2 over 30 minute(s) by intravenous route once daily for 5 consecutive days starting on day 1 of a 21 day course
4 mg intravenous solution
- Infuse 1.5 mg/m2 over 30 minute(s) by intravenous route once daily for 5 consecutive days starting on day 1 of a 21 day course
0.25 mg capsule
- Dosage information is not available
1 mg capsule
- Dosage information is not available
Carcinoma of cervix
- Infuse 0.75 mg/m2 over 30 minute(s) by intravenous route on days 1 through 3 of a 21 day treatment cycle
Malignant neoplasm of the ovary
- Infuse 1.5 mg/m2 over 30 minute(s) by intravenous route once daily for 5 consecutive days starting on day 1 of a 21 day course
Small cell lung carcinoma
- Infuse 1.5 mg/m2 over 30 minute(s) by intravenous route once daily for 5 consecutive days starting on day 1 of a 21 day course
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- amiodarone
- amiodarone in dextrose,iso-osm
- amoxicil-clarithromy-lansopraz
- Anti-allergy Formula
- ascorbate calcium-B5-quercetin
- azithromycin
- B3,azel,quer&tur-FA-B6-zn-copp
- Biaxin
- Biaxin Xl
- Biaxin Xl Pak
- Bilberry Extract
- bilberry-rutin-bioflav-quercet
- Bosulif
- bosutinib
- Calan
- Calan Sr
- captopril
- captopril-hydrochlorothiazide
- Cardizem
- Cardizem Cd
- Cardizem La
- Cartia Xt
- carvedilol
- carvedilol phosphate
- Cerebyx
- clarithromycin
- clozapine
- Clozaril
- conivaptan in 5 % dextrose
- Cordarone
- Coreg
- Coreg Cr
- cyclosporine
- cyclosporine modified
- deferiprone
- dextromethorphan-quinidine
- Dilacor Xr
- Dilantin
- Dilantin Extended
- Dilantin Infatabs
- Dilantin Kapseal
- Dilantin-125
- Dilt-xr
- diltiazem HCl
- dronedarone
- Erythrocin
- erythromycin
- erythromycin-sulfisoxazole
- Fazaclo
- felodipine
- Ferriprox
- fosphenytoin
- Gengraf
- glucosam-csa-mv-min AA-hrb 162
- itraconazole
- Kaletra
- ketoconazole
- lopinavir-ritonavir
- mag oxide-D3-turmeric rt xt
- Matzim La
- Maximum Daily Green
- me-thfolate gluc-B12-herb #236
- milk prot-turm-pepper-pinea ex
- Minus Weight Plus Energy
- Multaq
- mv-iron-FA-Ca-beepoln-hb 101
- Neoral
- Nexterone
- Nicazel Forte
- Norvir
- Norvir Soft Gelatin
- Nuedexta
- nut.tx, metab.dis, mv & min #4
- Omeclamox-pak
- omeprazole-clarith-amoxicillin
- Onmel
- Pacerone
- Phenytek
- phenytoin
- phenytoin sodium
- phenytoin sodium extended
- Prevpac
- Proteolin
- Proteolin Ds
- quinidine gluconate
- quinidine sulfate
- resveratrol-quercetin
- Rheumate
- ritonavir
- Sandimmune
- Sporanox
- Sporanox Pulsepak
- Tarka
- Taztia Xt
- Tiazac
- trandolapril-verapamil
- Ultra Inflamx Plus 360
- Vaprisol
- verapamil
- Verelan
- Verelan Pm
- Versacloz
- vit C-B6-B5-magnesium-hrb #173
- Xydra Ef
- Zithromax
- Zithromax Tri-pak
- Zithromax Z-pak
- Zmax
Severe
Moderate
- filgrastim
- Granix
- Leukine
- Neulasta
- Neupogen
- pegfilgrastim
- sargramostim
- tbo-filgrastim
- Interstitial lung disease
- Interstitial pneumonitis
- Lactating mother
- Severe anemia
- Severe bone marrow depression
- Severe neutropenic disorder
- Severe thrombocytopenia
Contraindicated
- Anemia
- Chronic kidney disease stage 3B (moderate) GFR 30-44
- Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min
- Neutropenic colitis
- Neutropenic disorder
- Pregnancy
- Renal disease with moderate to severe impairment
- Severe infection
- Thrombocytopenic disorder
Severe
Moderate
- Pulmonary fibrosis
- Radiation therapy involving the lungs
HYCAMTIN (TOPOTECAN HCL)
- Carcinoma of cervix
- Malignant neoplasm of the ovary
- Small cell lung carcinoma
- Anemia
- Diarrhea
- Dyspnea
- Fever
- Leukopenia
- Neutropenic disorder
- Pain
- Thrombocytopenic disorder
- Abdominal pain with cramps
- Alopecia
- Anorexia
- Arthralgias
- Constipation
- Cough
- Fatigue
- General weakness
- Headache disorder
- Hyperhidrosis
- Lethargy
- Malaise
- Nausea
- Paresthesia
- Stomatitis
- Vomiting
More Frequent
Severe
Less Severe
- Gastrointestinal obstruction
- Hyperbilirubinemia
- Infection
- Pneumonia
- Abnormal hepatic function tests
- Bone pain
- Chest pain
- Chills
- Dysmenorrhea
- Earache
- Neuropathic pain
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Allergic dermatitis
- Anaphylaxis
- Angioedema
- Bacterial sepsis
- Enterocolitis
- Gastrointestinal perforation
- Hemorrhage
- Interstitial lung disease
- Neutropenic colitis
- Pancytopenia
- Pruritus of skin
- Skin rash
Less Severe
- Dyspareunia
- Extravasation injury
- Peripheral sensory neuropathy
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Topotecan
Safety and efficacy not established.
- 1 Day – 18 Years
- Safety and efficacy not established.
Topotecan
- Severity Level:
D
- Additional Notes: Based on drug pharmacology developmental toxicity is possible.
Contraindicated
Topotecan
Contraindicated per manufacturer; potential for severe adverse effects
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Contraindicated per manufacturer; potential for severe adverse effects |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Topotecan
Renal-Adjust dose for decreased renal function of aging for CrCL <40 mL/min. Gastrointestinal- Treatment-related diarrhea was more frequent in patients aged greater than or equal to 65 years (28%).
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | N | N | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- Topotecan decreases bone marrow function. This effect may lead to a low number of blood cells such as red cells, white cells, and platelets. A low number of blood cells can cause anemia, decrease your body's ability to fight an infection, or cause your body to bruise or bleed more easily.<br /><br />Tell your doctor right away if you develop any of the following symptoms: unusual tiredness, pale skin, signs of infection (such as sore throat that doesn't go away, fever, chills), easy bruising/bleeding. Your doctor will order frequent blood tests to monitor your bone marrow function while you are taking this medication. Keep all medical and laboratory appointments.
| Carcinoma of cervix | |
| C53 | Malignant neoplasm of cervix uteri |
| C53.0 | Malignant neoplasm of endocervix |
| C53.1 | Malignant neoplasm of exocervix |
| C53.8 | Malignant neoplasm of overlapping sites of cervix uteri |
| C53.9 | Malignant neoplasm of cervix uteri, unspecified |
| Malignant neoplasm of the ovary | |
| C56 | Malignant neoplasm of ovary |
| C56.1 | Malignant neoplasm of right ovary |
| C56.2 | Malignant neoplasm of left ovary |
| C56.9 | Malignant neoplasm of unspecified ovary |
| Small cell lung carcinoma | |
| C34 | Malignant neoplasm of bronchus and lung |
| C34.0 | Malignant neoplasm of main bronchus |
| C34.00 | Malignant neoplasm of unspecified main bronchus |
| C34.01 | Malignant neoplasm of right main bronchus |
| C34.02 | Malignant neoplasm of left main bronchus |
| C34.1 | Malignant neoplasm of upper lobe, bronchus or lung |
| C34.10 | Malignant neoplasm of upper lobe, unspecified bronchus or lung |
| C34.11 | Malignant neoplasm of upper lobe, right bronchus or lung |
| C34.12 | Malignant neoplasm of upper lobe, left bronchus or lung |
| C34.2 | Malignant neoplasm of middle lobe, bronchus or lung |
| C34.3 | Malignant neoplasm of lower lobe, bronchus or lung |
| C34.30 | Malignant neoplasm of lower lobe, unspecified bronchus or lung |
| C34.31 | Malignant neoplasm of lower lobe, right bronchus or lung |
| C34.32 | Malignant neoplasm of lower lobe, left bronchus or lung |
| C34.8 | Malignant neoplasm of overlapping sites of bronchus and lung |
| C34.80 | Malignant neoplasm of overlapping sites of unspecified bronchus and lung |
| C34.81 | Malignant neoplasm of overlapping sites of right bronchus and lung |
| C34.82 | Malignant neoplasm of overlapping sites of left bronchus and lung |
| C34.9 | Malignant neoplasm of unspecified part of bronchus or lung |
| C34.90 | Malignant neoplasm of unspecified part of unspecified bronchus or lung |
| C34.91 | Malignant neoplasm of unspecified part of right bronchus or lung |
| C34.92 | Malignant neoplasm of unspecified part of left bronchus or lung |
| C39.9 | Malignant neoplasm of lower respiratory tract, part unspecified |
| 0-9 | A-Z |
|---|---|
| C34 | Malignant neoplasm of bronchus and lung |
| C34.0 | Malignant neoplasm of main bronchus |
| C34.00 | Malignant neoplasm of unspecified main bronchus |
| C34.01 | Malignant neoplasm of right main bronchus |
| C34.02 | Malignant neoplasm of left main bronchus |
| C34.1 | Malignant neoplasm of upper lobe, bronchus or lung |
| C34.10 | Malignant neoplasm of upper lobe, unspecified bronchus or lung |
| C34.11 | Malignant neoplasm of upper lobe, right bronchus or lung |
| C34.12 | Malignant neoplasm of upper lobe, left bronchus or lung |
| C34.2 | Malignant neoplasm of middle lobe, bronchus or lung |
| C34.3 | Malignant neoplasm of lower lobe, bronchus or lung |
| C34.30 | Malignant neoplasm of lower lobe, unspecified bronchus or lung |
| C34.31 | Malignant neoplasm of lower lobe, right bronchus or lung |
| C34.32 | Malignant neoplasm of lower lobe, left bronchus or lung |
| C34.8 | Malignant neoplasm of overlapping sites of bronchus and lung |
| C34.80 | Malignant neoplasm of overlapping sites of unspecified bronchus and lung |
| C34.81 | Malignant neoplasm of overlapping sites of right bronchus and lung |
| C34.82 | Malignant neoplasm of overlapping sites of left bronchus and lung |
| C34.9 | Malignant neoplasm of unspecified part of bronchus or lung |
| C34.90 | Malignant neoplasm of unspecified part of unspecified bronchus or lung |
| C34.91 | Malignant neoplasm of unspecified part of right bronchus or lung |
| C34.92 | Malignant neoplasm of unspecified part of left bronchus or lung |
| C39.9 | Malignant neoplasm of lower respiratory tract, part unspecified |
| C53 | Malignant neoplasm of cervix uteri |
| C53.0 | Malignant neoplasm of endocervix |
| C53.1 | Malignant neoplasm of exocervix |
| C53.8 | Malignant neoplasm of overlapping sites of cervix uteri |
| C53.9 | Malignant neoplasm of cervix uteri, unspecified |
| C56 | Malignant neoplasm of ovary |
| C56.1 | Malignant neoplasm of right ovary |
| C56.2 | Malignant neoplasm of left ovary |
| C56.9 | Malignant neoplasm of unspecified ovary |
Formulary Reference Tool